The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1352
Miconazole (Oravig) for Oropharyngeal Candidiasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a buccal tablet formulation of miconazole (Oravig – Strativa) for local treatment of oropharyngeal candidiasis in adults. Miconazole has been available for many years in topical formulations for treatment of superficial fungal infections and vulvovaginal candidiasis.1

OROPHARYNGEAL CANDIDIASIS — Clotrimazole troches or nystatin suspension are often used for initial treatment of mild to moderate oropharyngeal candidiasis. Compliance can be a problem because of the need for multiple doses, and recurrence is common. For treatment of recurrent or more severe disease, systemic fluconazole is often used, but development of resistance has been reported.2

PHARMACOLOGY — Miconazole is an azole antifungal with activity against many species of Candida, including some resistant to fluconazole.3 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Miconazole (Oravig) for Oropharyngeal Candidiasis
Article code: 1352d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian